Depotwettbewerb USA 25 KW
Man kann leider nicht alle genialen Shares haben, sind viele wie TRAD, NENG, SYNO, DAKT, USNA, etc. nicht berücksichtigt. Es sollte aber auch so funzen.
Gruss E.
AMRN 3,02 2708 8178,16 2,72§
EZEN 0,50 16400 8200,00 0,45§
EMTI 0,20 41000 8200,00 0,18§
EMIS 5,11 1600 8176,00 4,60§
JNIC 5,15 1585 8162,75 4,64§
OME 5,50 1486 8173,00 4,95§
PHLI 1,12 7303 8179,36 1,01§
PUMA 3,99 2050 8179,50 3,59§
MRBA 3,40 2405 8177,00 3,06§
NFLD 9,20 888 8169,60 8,28§
MCHM 1,38 5926 8177,88 1,24§
GNBT 2,39 3422 8178,58 2,15§
§98151,83 145,38 0,00 -100,00 -100,00
Mit den News heute noch kaufen.
Gruss E.
Amarin Corporation and Acadia Pharmaceuticals Sign Pharmaceutical Development Agreement
LONDON, Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amarin Corporation
plc (Nasdaq: AMRN) today confirmed that its Swedish subsidiary, Amarin
Development AB, has been engaged to provide pharmaceutical formulation and
manufacturing services for ACADIA Pharmaceuticals, based in San Diego,
California and Copenhagen, Denmark. The deal centers on the continued
development of ACADIA's small molecule drug candidate ACP-103, currently in
Phase I clinical studies. ACADIA intends to utilize Amarin's services in
connection with additional clinical studies planned for ACP-103 for the
treatment of neuropsychiatric and neurological disorders.
Rick Stewart, CEO of Amarin, commented on the successful deal, "The selection of
Amarin Development by ACADIA to provide these services underscores our
strengthened position as a global product development company. This agreement
additionally makes use of Amarin's expertise in neurology and complements the
research and development activities of Amarin Pharmaceuticals Inc. in the US,
making this a particularly attractive signing."
About ACP-103
ACP-103 is initially being pursued as a therapy for treatment-induced
dysfunctions in Parkinson's disease, an indication that lacks adequate drug
therapy. Due to its unique profile, ACP-103 may also have broad utility in a
range of other important indications. ACP-103 is a proprietary small molecule
that acts as a selective inverse agonist at the 5-HT2A receptor.
About Amarin
Amarin Corporation plc is a specialty pharmaceutical company focused on
neurology and pain management. Amarin has multiple pharmaceutical products on
the US market along with a development pipeline that includes two late-stage
candidates: Zelapar (selegiline HCl orally disintegrating tablets) for
Parkinson's disease and LAX-101, a proprietary compound for Huntington's
Disease. For press releases and other Company information, visit our websites at
http://www.amarincorp.com and http://www.amarinpharma.com.
About ACADIA
ACADIA Pharmaceuticals is a drug discovery and development company that
efficiently discovers novel small molecule drug candidates using its proprietary
chemical-genomics platform. ACADIA has applied its platform to generate a broad
discovery pipeline directed at large unmet medical needs including Parkinson's
disease, chronic pain, psychosis, and glaucoma. Two of ACADIA's drug candidates
have been successfully advanced from initial discovery to clinical development,
and several additional programs are in late-stage preclinical testing. ACADIA's
corporate headquarters as well as its biological research facilities are located
in San Diego, California and its chemistry research facilities are located in
Copenhagen, Denmark.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties which may cause
the Company's actual results in future periods to be materially different from
any performance suggested herein. Such risks and uncertainties include, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development and commercialization, the impact of competitive
products and patents, as well as other risks and uncertainties detailed from
time to time in periodic report, including but not limited to the filing or
approval of the NDA for Zelapar. For more information, please refer to Amarin
Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed
with the U.S. Securities and Exchange Commission. The Company assumes no
obligation to update information on its expectations.
SOURCE Amarin Corporation plc
Consolidated Real-time Market Quote*
| Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
| 3.22 |  0.21 (6.98) | N/A | 3.18 (5) | 3.25 (2) | 12:44 |
Exchange Quote
| Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
| 3.27 | 0.26 (8.64) | 3.23 (3) | 3.25 (2) | 13:06 |
| Day Volume | Last Size | Open | High | Low |
| 178,900 | 500 | 3.10 | 3.33 | 3.07 |
| Latest Ticks | # of Trades | Avg Trade Size | VWAP | 52 Wk High |
| ===+ | 237 | 755 | 3.1987 | 8.55 |
| 52 Wk Low | Prev Close | Avg Day Vol | ||
| 2.15 | 3.01 | 149,300 |
1:40:31 PM EDT - Thursday, June 19, 2003- Exchange quote is delayed at least 15 minutes
4 Dollar sollten drin sein, meine Meinung !
Schulden weiter abgebaut, Matrix scheint gut anzulaufen...
IMAX Corporation Announces Retirement of $22 Million of Debt
THURSDAY, JUNE 19, 2003 7:00 AM
- PR Newswire
TORONTO, Jun 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- IMAX Corporation(Nasdaq: IMAX; TSX: IMX) today announced that it has retired approximately $22 million in face value of its $200 million of senior notes due December 2005 in exchange for newly-issued common shares of the Company. After giving effect to these transactions, approximately $178 million of the notes remain outstanding. When combined with the Company's prior debt retirements in 2001 and 2002, IMAX has reduced its total debt by more than 40% in less than two years.
"The retirement of approximately ten percent of outstanding debt is important for IMAX and we believe that this reduction facilitates our ability to refinance the remainder of the debt before December 2005 on favorable terms," said Richard L. Gelfond and Bradley J. Wechsler, IMAX's Co-Chairmen and Co-Chief Executive Officers. "Although the senior note issue is not due for another two and a half years, we are committed to improving the Company's balance sheet and will continue to seek opportunities to do so."
"Over just the last six weeks, the Company has eliminated a significant share overhang resulting from the holdings of former shareholder Wasserstein Partners, LP, successfully released The Matrix Reloaded: The IMAX Experience and now eliminated a significant portion of our remaining debt," added Messrs. Gelfond and Wechsler.
The $22 million in face value of senior notes were exchanged for approximately 2.9 million shares of IMAX common stock.
Bei FSST und HMSL mit fetten Tausenderpositionen reichlich Prozente gesammelt, wenn ich mich nicht irre.
Glückwunsch sach ich da ma !
Ich bin leider komplett flat.
12 gruene Werte und 12x gruener Mist, datt muss man erstma schaffen!
Nächste Woche hab ich nur gelengentlich Zeit für die Börse.
Deshalb wird es wohl auch hier, genau wie bei Happy, eine Woche lang ein 100prozentiges Cash- Depot geben.
Viel Trading- Glück für die KW 26 wünscht euch
Optionen
| Boardmail an "Gruenspan" |
Wertpapier: Huaneng Power ADR |
Am Montag war INGN nachbörslich noch bei 8, jetzt geschlossen zu 5. Künstlerpech.
Na, EZEN hat mir nen minimales Plus gerettet, immerhin.
reinyboy rückt mir auf den Pelz, nächste Woche werde ich wieder besser.
Ich werd auf keinen Fall mehr nen Share kaufen, über den ich aber so gar nichts weiss,
so wie EMTI diese Woche, ausser das EMTI von 0,005! auf 0,20 gestiegen war.
So was Dummes muss bestraft werden, irgend eine Bude zu kaufen, die man gar nicht kennt.
Gruss E.
Schön,dass nach 8 Wochen Sommer in Berlin endlich heute der Herbst Einzug gehalten hat, 16 C, Wind und Regen,die besten Voraussetzungen für die geplante Gartenparty.
Ach so: Kann ich die SL von letzter Woche behalten,z.B bei DNDN?
Ciao B.L.
FSST wurde ja glücklicherweise am letzten Dienstag zu 0.22 $ versilbert. Inzwischen liegen die ja auch da wo sie hingehören bei unter 10 Cent.
Verkauft wird nun alles was noch im Depot ist:
SONT = 18018$
IMA = 11070$
HMSL = 23680$
Gekauft wird :
KRY 6250 Stück zu SK 1.60$ = 10000$
CAU 7000 Stück zu SK 1.40$ = 9800$
WHT 8000 Stück zu SK 1.22$ = 9760$
MNG 7500 Stück zu SK 1.26$ = 9450$
GSS 3700 Stück zu SK 2.71$ = 10027$
VGZ 2900 Stück zu SK 3.40$ = 9860$
IAG 1800 Stück zu SK 5.21$ = 9899$
KGC 1500 Stück zu SK 6.97$ = 10455$
BVN 320 Stück zu SK 30.99$ = 9916.80$
Ich weiß, das Depot ist nun sehr einseitig, aber ich glaube an ne outperformence für die nächste Woche ( Wochen??).
Grüße Reiny
Danke erstmal für deine Wochenabrechnung!
Katastrophale 5 Tage für meine 12 Heifleier is datt geworden.
Und du sprachst noch vor Tagen vom gruenen Wochengewinner *gg*!
Ich Keule hab am Ende aber doch noch so richtig Pech jehabt, Künstlerpech eben!
Ein bisschen Zeit is aber um neue Absacker fürs gruene Depot zu suchen.
Obwohl ich nächste Woche (hauptsächlich Nachmittags) echt kaum Zeit für den Markt habe,
trete ich an.
82368 Dollar stehen zur Verfügung.
8 Werte werden aufgenommen.
82368 : 8 = 10296!
Macht also 10296 je Position.
01 GILTF KK 5,19 (Stk. 1984 ) = 10296
02 SLGLF KK 0,21 (Stk. 49028) = 10296
03 BOAI KK 0,13 (Stk. 79200) = 10296
04 FAIM KK 1,72 (Stk. 5986 ) = 10296
05 CHINA KK 7,29 (Stk. 1412 ) = 10296
06 IPIX KK 4,74 (Stk. 2172 ) = 10296
07 EONC KK 1,40 (Stk. 7354 ) = 10296
08 AEGN KK 0,68 (Stk. 15141) = 10296
So, ma gucken, watt meine schnell aus der Hüfte geschossenen Werte in den nächsten Tagen veranstalten.
2 Tage FED Sitzung und viele US- Wirtschaftsdaten sollten für reichlich Bewegung am Aktienmarkt sorgen.
Fragt sich nur in welche Richtung!?
Eigentlich erscheint es aus diesem Grund eher sinnvoll etwas an der Aktien- Seitenlinie zu warten, aber ganz ohne "Spielspass" macht es wenig Laune!
Deshalb, keine Runde ohne
Optionen
| Boardmail an "Gruenspan" |
Wertpapier: Huaneng Power ADR |
ICGE ist ja ausgestopt worden(eigentlich erstaunlich, dass es nach dem Run nur noch bergab ging) - demnach Cash=31612$
Neu ins Depot wandert TRAD(300*10=3000$/Cash=28612$), nachdem die Umsätze weiterhin hoch sind an den Börsen, sollte sich das auch bei den Zahlen von TRAD auswirken. SL setze ich bei 8,9!
Ansonsten bleibt alles wie bisher.
Glückwunsch an Reiny für das gute Timing mit der Pleiteaktie und an B.L mit RAEE!
Danke für die Arbeit, Eskimato und auf eine erfolgreichere Woche!
Bestand:
ACLA 4000 x 4,25 = 17000,00 SL bleibt
GENR 7050 x 2,29 = 16144,50 SL bleibt
AVCI 2900 x 5,84 = 16936,00 SL bleibt
TMR 4300 x 4,04 = 17587,00 SL NEU 3,68
CASH = 62830,04
KAUF:
INGN 1550 x 5,00 = 7750,00 SL 4,50
FMXI 2600 x 3,00 = 7800,00 SL 2,70
ACTU 2500 x 3,15 = 7875,00 SL 2,84
NTPA 1800 x 4,34 = 7812,00 SL 3,91
FMT 560 x 14,02 = 7851,20 SL 12,62
IPIX 1650 x 4,74 = 7821,00 SL 4,27
KERX 4000 x 2,01 = 8040,00 SL 1,81
KIWI 49255 x 0,16 = 7880,80 SL 0,14
Wünsche allen eine schöne Woche mit Erfolg !
Greetz f-h
Ich verkaufe noch INAP 5000 + 1.26 = 6.300 + Cash Verkauf RAEE 7.400= 13.700
Neue Positionen:
1000 CHINA KK 7.29 Wert: 7.290,--
1000 INGN KK 5.00 Wert: 5.000,--
47000 GMED KK 0.03 Wert: 1.410,--
Alles andere bleibt;bitte auch die "alten" SL.
Schönen Sonntag noch B.L.
Gruss E.
Adept Technology Selected by Tegal's Sputtered Films Subsidiary to Provide Automated Reticle Handling for Thin-Film Deposition Tool Thin-Film Deposition Tool to Include Adept's Reticle Loading Front-End Module, Integrated Robot, Loadport, I/O and Hos
LIVERMORE, Calif., Jul 14, 2003 (BUSINESS WIRE) -- Adept Technology, Inc.
(OTCBB:ADTK.OB), a leading manufacturer of flexible automation for the
semiconductor, electronics, fiber optic, telecommunications, and life sciences
industries, today announced that the Sputtered Films subsidiary of Tegal
Corporation (Nasdaq: TGAL), a leading semiconductor manufacturer, has selected
Adept Technology to provide automated reticle handling for its thin-film
deposition tool.
Tegal's Sputtered Films Endeavor EUVL tool will utilize the new Adept Reticle
Loading Front-End Module (RLFEM), which includes Adept robots, controls,
software and clean air system technology. The Adept RLFEM(TM) platform is the
only reticle handling front-end platform that incorporates the control of robot,
end-effector, SMIF pod, I/O and host connectivity in a single cell controller
and software application environment, which increases reliability, simplifies
system maintainability, and lowers overall cost of ownership.
"Sputtered Films is a leading provider of advanced technology, thin-film
deposition semiconductor process tools and we are excited about partnering with
them to develop a reticle handling platform that meets their specific
requirements," said Charlie Duncheon, executive vice president of Adept
Technology.
"Adept Technology's innovative designs, solid record for product reliability,
and excellent customer service made them an attractive choice for us," said
Carole Anne Demachkie, general manager of Sputtered Films. "We look forward to
the receipt of the automated handling platform they've designed to interface
with our state-of-the-art Endeavor EUVL tool."
The Adept RLFEM(TM) platform provides fully automated transfer of photomasks
between reticle SMIF-pods and SFI's thin-film deposition process tool. It
utilizes an Adept wafer and reticle handling robot, the Adept SMIF-EZ load port
and a reticle flipping station. It also utilizes Adept's AIM SemiWare(TM), a
patented, database-driven application development environment which interfaces
with the host controller through either RS-232 or SECS/GEM protocols. The Adept
RLFEM platform has a compact but flexible design and meets stringent ISO Class 2
cleanliness standards. It features a clean, edge-contact reticle end-effector,
independent reticle flip station and single cell controller for all robot,
loadport, I/O and host controller connectivity.
Tegal Corporation, headquartered in Petaluma, Calif., is a leading designer and
manufacturer of plasma etch and deposition systems used in the production of
MEMS, smart cards, opto-telecom devices, integrated circuits (ICs), and other
related microelectronics devices. Both etching and deposition are key process
steps and must be repeated multiple times in the production of these devices.
Tegal markets and services its systems in all major IC-producing regions of the
world. More information is available on the Internet at: www.tegal.com.
Adept Technology designs, manufactures and markets factory automation components
and systems for the fiber optic, telecommunications, semiconductor, automotive,
food and durable goods industries throughout the world. Adept's robots,
controllers, and software products are used for small parts assembly, material
handling and ultra precision process applications. Our intelligent automation
product lines include industrial robots, configurable linear modules, flexible
feeders, semiconductor process components, nanopositioners, machine controllers
for robot mechanisms and other flexible automation equipment, machine vision,
systems and software, application software, and simulation software. Founded in
1983, Adept is America's largest manufacturer of industrial robots. More
information is available at www.adept.com.
This press release contains certain forward-looking statements that involve a
number of risks and uncertainties. Actual results could vary for a number of
reasons, including, but not limited to, the potential delays associated with the
development and introduction of new products or software releases; rapid
technological change within the company's industry; and the potential that our
new or existing products may contain defects, errors or performance problems.
For a discussion of additional risk factors relating to Adept's business, see
Adept's annual report on Form 10-K for the fiscal year ended June 30, 2002, as
amended, and Adept's quarterly reports on Form 10-Q for the quarters ended
September 28, 2002, as amended, December 28, 2002, as amended, and March 29,
2003, including the discussion in Management's Discussion and Analysis of
Financial Condition and Results of Operations contained therein.
The Adept logo is a registered trademark of Adept Technology, Inc. Adept, Adept
RLFEM, Adept SMIF-EZ, and Adept AIM SemiWare are trademarks of Adept Technology.
All other trademarks are owned by their respective companies.
SOURCE: Adept Technology, Inc.